Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

E. John Orav, Ph.D.

Co-Author

This page shows the publications co-authored by E. Orav and Howard Weiner.
Connection Strength

0.972
  1. Double-blind study of true vs. sham plasmapheresis in patients being treated with immunosuppression for acute attacks of multiple sclerosis. Prog Clin Biol Res. 1990; 337:283.
    View in: PubMed
    Score: 0.106
  2. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology. 1989 Sep; 39(9):1143-9.
    View in: PubMed
    Score: 0.104
  3. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler. 2005 Oct; 11(5):573-82.
    View in: PubMed
    Score: 0.079
  4. Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Arch Neurol. 2001 Jan; 58(1):115-21.
    View in: PubMed
    Score: 0.057
  5. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol. 2000 Aug; 57(8):1183-9.
    View in: PubMed
    Score: 0.055
  6. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol. 2000 May 01; 104(2):164-73.
    View in: PubMed
    Score: 0.054
  7. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler. 1999 Dec; 5(6):403-9.
    View in: PubMed
    Score: 0.053
  8. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler. 1999 Oct; 5(5):349-54.
    View in: PubMed
    Score: 0.052
  9. Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. Neurology. 1999 Sep 11; 53(4):758-64.
    View in: PubMed
    Score: 0.052
  10. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol. 1997 Aug; 54(8):1018-25.
    View in: PubMed
    Score: 0.045
  11. Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. Ann N Y Acad Sci. 1996 Feb 13; 778:243-50.
    View in: PubMed
    Score: 0.041
  12. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995 Feb; 45(2):251-5.
    View in: PubMed
    Score: 0.038
  13. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology. 1994 Nov; 44(11):2120-4.
    View in: PubMed
    Score: 0.037
  14. Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 1993 Sep 24; 261(5129):1727-30.
    View in: PubMed
    Score: 0.034
  15. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993 May; 43(5):910-8.
    View in: PubMed
    Score: 0.034
  16. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993 Feb 26; 259(5099):1321-4.
    View in: PubMed
    Score: 0.033
  17. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol. 1991 May; 32(2):149-58.
    View in: PubMed
    Score: 0.029
  18. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology. 1988 Jul; 38(7 Suppl 2):9-14.
    View in: PubMed
    Score: 0.024
  19. Cumulative experience with high-dose intravenous cyclophosphamide and ACTH therapy in chronic progressive multiple sclerosis. Ann N Y Acad Sci. 1988; 540:535-6.
    View in: PubMed
    Score: 0.023
  20. Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol. 2005 May; 62(5):795-800.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.